These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
20 related articles for article (PubMed ID: 8093845)
1. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Kakuda TN; Page LM; Anderson PL; Henry K; Schacker TW; Rhame FS; Acosta EP; Brundage RC; Fletcher CV Antimicrob Agents Chemother; 2001 Jan; 45(1):236-42. PubMed ID: 11120972 [TBL] [Abstract][Full Text] [Related]
2. Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients. Adams JM; Shelton MJ; Hewitt RG; Grasela TH; DeRemer M; Morse GD Antimicrob Agents Chemother; 1998 Apr; 42(4):821-6. PubMed ID: 9559790 [TBL] [Abstract][Full Text] [Related]
3. Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents. Burger DM; Meenhorst PL; Beijnen JH Pharm World Sci; 1995 Mar; 17(2):25-30. PubMed ID: 7795555 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Stretcher BN Clin Pharmacokinet; 1995 Jul; 29(1):46-65. PubMed ID: 7586898 [TBL] [Abstract][Full Text] [Related]
5. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189 [TBL] [Abstract][Full Text] [Related]
6. Didanosine therapy in patients intolerant of or failing zidovudine therapy. Rathbun RC; Martin ES Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093 [TBL] [Abstract][Full Text] [Related]
7. Didanosine: long-term follow-up of patients in a phase 1 study. Lambert JS; Seidlin M; Valentine FT; Reichman RC; Dolin R Clin Infect Dis; 1993 Feb; 16 Suppl 1():S40-5. PubMed ID: 8093846 [TBL] [Abstract][Full Text] [Related]
8. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651 [TBL] [Abstract][Full Text] [Related]
9. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection. Nguyen BY; Shay LE; Wyvill KM; Pluda JM; Brawley O; Cohen RB; Whitcup SM; Venzon DJ; Broder S; Yarchoan R J Infect Dis; 1993 Oct; 168(4):810-7. PubMed ID: 8397267 [TBL] [Abstract][Full Text] [Related]
11. Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex. Beltangady M; Knupp CA; Gustafson N; Barbhaiya RH; Dolin R; Seidlin M; Cooley TP; Rozencweig M Clin Infect Dis; 1993 Feb; 16 Suppl 1():S26-31. PubMed ID: 8093845 [TBL] [Abstract][Full Text] [Related]